These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10945200)

  • 1. Cost-benefit analysis of a clinical pharmacist-managed medication assistance program in a renal transplant clinic.
    Chisholm MA; Vollenweider LJ; Mulloy LL; Wynn JJ; Wade WE; DiPiro JT
    Clin Transplant; 2000 Aug; 14(4 Pt 1):304-7. PubMed ID: 10945200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Financial Effect of Medicare Coverage Design and Safety Net Options for Cancer Care.
    Bethay SS; Travis MJ; Batt SK; Bochenek SH; Schwieterman PA
    J Manag Care Spec Pharm; 2020 Jan; 26(1):76-80. PubMed ID: 31880225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs?
    Chisholm MA; Marshall J; Smith KE; Garrett CJ; Turner JC
    Clin Transplant; 2005 Jun; 19(3):357-63. PubMed ID: 15877798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Medicare modernization act on low-income persons.
    Havrda DE; Omundsen BA; Bender W; Kirkpatrick MA
    Ann Intern Med; 2005 Oct; 143(8):600-8. PubMed ID: 16230727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PRICE clinic for low-income elderly: a managed care model for implementing pharmacist-directed services.
    Stebbins MR; Kaufman DJ; Lipton HL
    J Manag Care Pharm; 2005 May; 11(4):333-41. PubMed ID: 15871644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a Prescription-Assistance Program for Medically Uninsured Patients With Cancer: Case Study of a Public Hospital Experience in New York State.
    Gao L; Joseph J; Santoro-Levy M; Gotlieb VK; Multz AS
    J Oncol Pract; 2014 Mar; 10(2):104. PubMed ID: 29452556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assistance programs available for medications commonly used in transplant patients.
    Chisholm MA; Tackett KL; Kendrick BD; DiPiro JT
    Clin Transplant; 2000 Aug; 14(4 Pt 1):269-81. PubMed ID: 10945196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.
    Kadatz M; Gill JS; Gill J; Formica RN; Klarenbach S
    J Am Soc Nephrol; 2020 Jan; 31(1):218-228. PubMed ID: 31704739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit and cost-savings analyses of antiarrhythmic medication monitoring.
    Snider M; Carnes C; Grover J; Davis R; Kalbfleisch S
    Am J Health Syst Pharm; 2012 Sep; 69(18):1569-73. PubMed ID: 22935939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients.
    Gao L; Joseph J; Santoro-Levy M; Multz AS; Gotlieb VK
    Hosp Pharm; 2016 Jul; 51(7):572-6. PubMed ID: 27559190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceuticals: Medicare Modernization Act--2005. End of Year Issue Brief.
    Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-21. PubMed ID: 16710928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients.
    Page TF; Woodward RS
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):435-44. PubMed ID: 19817527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing medication access to transplant recipients.
    Chisholm M
    Clin Transplant; 2004 Feb; 18(1):39-48. PubMed ID: 15108769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytic dimensions of a prescription-medication benefit in medicare.
    Vogel RJ; Cox ER
    Clin Ther; 2000 Apr; 22(4):470-93. PubMed ID: 10823367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program.
    Etemad LR; Hay JW
    Value Health; 2003; 6(4):425-35. PubMed ID: 12859583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond pharmaceutical manufacturer assistance: broadening the scope of an indigent drug program.
    Weiner S; Dischler J; Horvitz C
    Am J Health Syst Pharm; 2001 Jan; 58(2):146-50. PubMed ID: 11202538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical manufacturer assistance programs.
    Chisholm MA; DiPiro JT
    Arch Intern Med; 2002 Apr; 162(7):780-4. PubMed ID: 11926851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription drugs in Medicare and the ESRD program.
    Powe NR
    Semin Nephrol; 2000 Nov; 20(6):535-42. PubMed ID: 11111855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient assistance programs and patient advocacy foundations: alternatives for obtaining prescription medications when insurance fails.
    Johnson PE
    Am J Health Syst Pharm; 2006 Nov; 63(21 Suppl 7):S13-7. PubMed ID: 17057055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.